Alaunos Therapeutics (TCRT) investor relations material

Executive summary

• Focus shifted to preclinical, oral small-molecule therapeutics for obesity and metabolic disorders, with ALN1003 showing positive proof-of-concept in DIO mouse models, including dose-dependent weight loss and improved metabolic markers.

• No product revenue generated; net loss of $4.2 million for 2025 and accumulated deficit of $924.6 million as of year-end.

• Strategic reprioritization in August 2023 led to discontinuation of TCR-T oncology programs and a 95% workforce reduction.

Financial highlights

• Net loss for 2025 was $4.2 million, improved from $4.7 million in 2024.

• Research and development expenses increased to $1.4 million (up $1.0 million year-over-year) due to obesity program expansion.

• General and administrative expenses decreased 36% to $2.9 million, reflecting cost-saving measures.

• Cash and cash equivalents at year-end were $1.4 million; working capital was $1.2 million.

• No product revenue; minimal royalty income ($5,000 in 2025).

Outlook and guidance

• Cash runway expected to last into Q2 2026; substantial additional capital required to continue operations and advance the obesity program.

• Plans to conduct further preclinical studies, optimize formulations, and pursue IND-enabling activities for ALN1003, contingent on funding.

• Actively exploring strategic financing and collaboration opportunities.